title: Loss of p27 expression is associated with poor prognosis in stage I-II pancreatic cancer.
abstract: OBJECTIVE
  p27 is a cyclin-dependent kinase inhibitor that prevents progression of the cell cycle from G1 phase. Postranscriptional loss of p27 correlates with poor prognosis in various solid tumors. In pancreatic cancer, the loss of p27 expression has been correlated with high tumor grade and advanced clinical stage, but data on its prognostic value are lacking.
  
  
  METHODS
  In this retrospective study, the association between immunohistochemical p27 expression and prognosis was evaluated in 147 patients with pancreatic cancer using a commercial anti-Kip1/p27 monoclonal antibody.
  
  
  RESULTS
  p27 expression was generally low; in 103 of the 147 pancreatic cancer tumors examined, no nuclear staining was observed and in only 5 specimens did more than 50% of the nuclei stain, probably reflecting the aggressive nature of the disease. Loss of p27 expression was associated with poor prognosis in stage I-II pancreatic adenocarcinoma; the 5-year survival for p27 negative patients was 3.6% compared with 20% for p27-positive patients (p = 0.03). In a multivariate survival analysis in patients with stage I-II disease, p27 (HR 1.8) was a significant prognostic factor, independent of grade (RR 2.9). There was no association between p27 and other clinical variables. In conclusion, tissue expression of p27 is a significant predictor of 5-year survival in stage I-II pancreatic adenocarcinoma.
authors.affiliation: Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland.
authors.forename: A
authors.initials: A
authors.lastname: Juuti
authors.forename: S
authors.initials: S
authors.lastname: Nordling
authors.forename: J
authors.initials: J
authors.lastname: Louhimo
authors.forename: J
authors.initials: J
authors.lastname: Lundin
authors.forename: K
authors.initials: K
authors.lastname: von Boguslawski
authors.forename: C
authors.initials: C
authors.lastname: Haglund
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008840:Microfilament Proteins / Q000032:analysis*; D008875:Middle Aged; D015999:Multivariate Analysis; D009124:Muscle Proteins; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000737:chemistry* / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D008840:Microfilament Proteins; D009124:Muscle Proteins; C058992:Tagln protein, mouse